aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ATYR
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
78.69 | 72.13 | 98.17 | 66.15 | 107.91 | 31.69 | 31.14 | 49.55 | 85.12 | 72.15 |
Receivables |
0.87 | 1.74 | 2.44 | 11.78 | 0.44 | 2.04 | 0.10 | — | — | — |
Total current assets |
80.24 | 81.95 | 102.99 | 80.87 | 113.57 | 35.53 | 31.93 | 50.80 | 86.99 | 74.77 |
Property, Plant, Equpment (Net) |
4.26 | 4.85 | 5.53 | 3.06 | 0.54 | 0.90 | 1.27 | 1.85 | 2.28 | 1.42 |
Long-Term Investments |
— | — | — | — | — | — | — | — | — | 4.00 |
Long-term assets (Other) |
2.38 | 3.02 | 3.62 | 3.36 | 0.16 | 0.21 | 0.17 | 0.09 | 0.09 | 0.33 |
Total non-current assets |
12.77 | 14.88 | 17.66 | 14.92 | 1.97 | 3.20 | 4.26 | 1.94 | 2.37 | 5.76 |
Total Assets |
93.00 | 96.83 | 120.65 | 95.79 | 115.54 | 38.73 | 36.19 | 52.75 | 89.36 | 80.52 |
Notes Payable |
— | — | — | — | — | — | 8.74 | — | — | — |
Accounts Payable |
3.89 | 4.32 | 3.53 | 3.11 | 1.03 | 1.43 | 0.85 | 1.04 | 2.28 | 2.61 |
Accrued Expenses |
9.79 | 9.39 | 11.56 | 9.86 | 4.00 | 3.57 | 2.38 | 2.03 | 3.10 | 5.45 |
Current Part of Debt |
— | — | — | — | — | — | — | 7.77 | 5.01 | 0.34 |
Current Part of Capital Lease |
0.63 | 0.54 | 0.50 | 0.26 | — | — | — | — | — | — |
Current Revenue (Deferred) |
— | — | — | — | — | — | — | — | — | 0.13 |
Other current liabilities |
— | — | — | — | — | — | 0.21 | 2.03 | 3.10 | 8.19 |
Total current liabilities |
15.15 | 14.97 | 16.42 | 13.86 | 6.01 | 5.86 | 12.92 | 10.83 | 10.39 | 8.53 |
Long Term Debt (Total) |
0.26 | 0.89 | 1.43 | 1.01 | 0.40 | 1.38 | 2.24 | 8.26 | 14.72 | 9.20 |
Total non-current liabilities |
10.57 | 12.03 | 13.77 | 10.64 | 0.40 | 1.38 | 2.24 | 8.26 | 14.72 | 9.20 |
Total liabilities |
25.72 | 27.00 | 30.18 | 24.50 | 6.41 | 7.24 | 15.16 | 19.10 | 25.11 | 17.72 |
Additional Paid In Capital |
673.55 | 602.02 | 558.69 | 489.50 | 481.83 | 370.21 | 343.52 | 332.41 | 328.52 | 278.83 |
Preferred Stock (Total) |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Common Stock (Net) |
0.10 | 0.08 | 0.06 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.03 | 0.02 |
Retained Earnings |
(606.16) | (532.05) | (468.02) | (417.63) | (372.30) | (338.53) | (322.30) | (298.70) | (264.19) | (215.98) |
Common Equity (Total) |
67.29 | 69.83 | 90.47 | 71.28 | 109.13 | 31.48 | 21.02 | 33.65 | 64.24 | 62.80 |
Shareholders Equity (Total) |
67.29 | 69.83 | 90.47 | 71.28 | 109.13 | 31.48 | 21.03 | 33.65 | 64.25 | 62.80 |
Shareholders Equity and Liabilities (Total) |
93.00 | 96.83 | 120.65 | 95.79 | 115.54 | 38.73 | 36.19 | 52.75 | 89.36 | 80.52 |
Shares (Common) |
98.03 | 84.04 | 63.29 | 29.50 | 27.79 | 11.02 | 3.89 | 2.19 | 2.13 | 1.70 |
Shares (Preferred) |
— | — | — | — | — | — | 1.64 | 2.29 | 0.16 | — |
Shareholders Equity (Tangible) |
67.29 | 69.83 | 90.47 | 71.28 | 109.13 | 31.48 | 21.03 | 33.65 | 64.25 | 62.80 |
Net Debt |
(78.43) | (71.24) | (96.74) | (65.14) | (107.51) | (30.31) | (28.90) | (33.51) | (65.39) | (62.61) |
Total Debt |
0.26 | 0.89 | 1.43 | 1.01 | 0.40 | 1.38 | 2.24 | 16.03 | 19.73 | 9.54 |